| SEC F | Form 4 |
|-------|--------|
|-------|--------|

FORM 4

Check this box if no longer subject to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

| OMB Number: | 3235-0287 | | | | | |
|--------------------------|-----------|--|--|--|--|--|
| Estimated average burden | | | | | | |
| hours per response: | 0.5 | | | | | |

| Section 16. F | form 4 or Form 5 ay continue. See b). | | iled pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 | | Estimated average burden hours per response: 0.5 |
|----------------------------------|---|-----------------------------|--|--|--|
| LYTLE PA (Last) C/O PEREGE | (First) | (Middle) CEUTICALS, INC. | 2. Issuer Name and Ticker or Trading Symbol PEREGRINE PHARMACEUTICALS INC [PPHM] 3. Date of Earliest Transaction (Month/Day/Year) 02/01/2010 | (Check all applicabl Director X Officer (giv below) | 10% Owner |
| (Street) TUSTIN, (City) | CA (State) | 92780 (Zip) | 4. If Amendment, Date of Original Filed (Month/Day/Year) | Line) X Form filed Form filed Person | tt/Group Filing (Check Applicable I by One Reporting Person I by More than One Reporting |
| | | Table I - Non-Der | ivative Securities Acquired, Disposed of, or Benefi | cially Owned | |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | Code (| | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | | | 5. Amount of Securities Beneficially Owned Following Reported | Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--|---|--------|---|--|---------------|-------|---|---|---|
| | | | Code | v | Amount | (A) or (D) | Price | Transaction(s) (Instr. 3 and 4) | | (11301 4) |
| Common Stock, \$0.001 par value | 02/01/2010 | | A | | 45,000 ⁽¹⁾ | Α | \$0 | 60,367 ⁽²⁾ | D | |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 3. Transaction Date 3A. Deemed Execution Date, 5. Number of Derivative 6. Date Exercisable and Expiration Date 7. Title and Amount of Securities 8. Price of Derivative 9. Number of derivative 10. Ownership 11. Nature of Indirect Conversion Trans ction or Exercise Price of (Month/Day/Year) if anv Code (Instr. 8) Securities (Month/Day/Year) Underlying Security Securities Form: Beneficial (Month/Day/Year) Acquired (A) Derivative Security (Instr. 5) Beneficially Direct (D) Ownership (Instr. 4)

| | Security | | | | | | and 5) | | (insu: 5 and 4) | | | Following Reported Transaction(s) | (I) (Instr. 4) | | |
|---|----------|------------|--|------|---|---------|--------|---------------------|--------------------|-----------------|-------------------------------------|---|----------------|---|--|
| | | | | Code | v | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | (Instr. 4) | | |
| Incentive Stock Option (right to buy) | \$2.93 | 02/01/2010 | | A | | 120,000 | | (3) | 02/01/2020 | Common Stock | 120,000 | (4) | 237,000 | D | |

Explanation of Responses:

1. These performance-based restricted shares were issued pursuant to a Stock Issuance Agreement dated February 1, 2010 and are subject to a vesting requirement based upon the timely attainment of certain predetermine clinical, financial and operational milestones. In this read, 20% of the performance-based restricted shares will vest upon the attainment of each predetermined milestone, which have targeted completion dates ranging from June 30, 2010 through July 15, 2011.

2. Includes performance-based restricted shares issued pursuant to a Stock Issuance Agreement dated February 1, 2010.

3. Option will vest quarterly in equal installments over a two year period.

4. n/a

1. Title of Derivative

Security

(Instr. 3)

Remarks:

/s/ Paul J. Lytle

** Signature of Reporting Person

02/03/2010

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Date